1. Home
  2. Faculty

Michael Henry, PhD

Professor of Molecular Physiology and Biophysics

Introduction

The long term research goals of my laboratory are to understand the molecular and cellular basis of prostate cancer progression and metastasis in order to develop new methods for the diagnosis and treatment of this disease. Current efforts are focused on the role of a cell-matrix receptor dystroglycan and epithelial-mesenchymal transition in this process. We approach this problem using both cell-based and animal models of disease progression. Emerging interests include how physiological and environmental components interact with central genetic pathways related to disease progression.

Current Positions

  • Professor of Molecular Physiology and Biophysics
  • Professor of Internal Medicine
  • Professor of Radiation Oncology
  • Professor of Pathology
  • Professor of Urology

Education

  • BS in Genetics, University of Georgia
  • PhD in Biology, Massachusetts Institute of Technology
  • Fellow, National Science Foundation
  • Fellow in Physiology and Biophysics, University of Iowa College of Medicine, Iowa City, Iowa

Graduate Program Affiliations

Center, Program and Institute Affiliations

Research Interests

  • The long term research goals of my laboratory are to understand the molecular and cellular basis of prostate cancer progression and metastasis in order to develop new methods for the diagnosis and treatment of this disease. Current efforts are focused on the role of a cell-matrix receptor dystroglycan and epithelial-mesenchymal transition in this process. We approach this problem using both cell-based and animal models of disease progression. Emerging interests include how physiological and environmental components interact with central genetic pathways related to disease progression

Selected Publications

  • Finnerty MC, Leach FE 3rd, Zakharia Y, Nepple KG, Bartlett MG, Henry MD, Cummings BS. Identification of blood lipid markers of docetaxel treatment in prostate cancer patients. Sci Rep. 2024 Sep 27;14(1):22069. doi: 10.1038/s41598-024-73074-8. PMID: 39333185; PMCID: PMC11436995.
  • Herndon ME, Ayers M, Gibson-Corley KN, Wendt MK, Wallrath LL, Henry MD, Stipp CS. The highly metastatic 4T1 breast carcinoma model possesses features of a hybrid epithelial/mesenchymal phenotype. Dis Model Mech. 2024 Sep 1;17(9):dmm050771. doi: 10.1242/dmm.050771. Epub 2024 Sep 4. PMID: 39104192; PMCID: PMC11391819.
  • Chang J, Campbell-Hanson KR, Vanneste M, Yevdash J, Bartschat NI, Jiang J, Bhinu A, Helverson A, Henry MD, Steingrímsson E, Weigel RJ, Cornell RA, Kenny C. An MITF- and mTOR-dependent FLCN pathway suppresses TFE3-driven metastasis in melanoma. bioRxiv [Preprint]. 2024 Jul 12:2024.07.11.603140. doi: 10.1101/2024.07.11.603140. PMID: 39026725; PMCID: PMC11257520.
  • Bi J, Witt E, McGovern MK, Cafi AB, Rosenstock LL, Pearson AB, Brown TJ, Karasic TB, Absler LC, Machkanti S, Boyce H, Gallo D, Becker SL, Ishida K, Jenkins J, Hayward A, Scheiflinger A, Bodeker KL, Kumar R, Shaw SK, Jabbour SK, Lira VA, Henry MD, Tift MS , Otterbein LE, Traverso G, Byrne JD. (2024) Oral Carbon Monoxide Enhancesn Autophagy Modulation in Prostate, Pancreatic, and Lung Cancers. Adv Sci (Weinh). Mar; 11(9):e2308346. DOI: 10.1002/advs.202308346. PMID: 38084435. PMCID: PMC10916612.
  • Vanneste M, Venzke A, Guin S, Fuller AJ, Jezewski AJ, Beattie SR, Krysan DJ, Meyers MJ, Henry MD. (2023) The anti-cancer efficacy of a novel phenothiazine derivative is independent of dopamine and serotonin receptor inhibition. Front Oncol. Oct 16; 13:1295185. DOI: 10.3389/fonc.2023.129515. PMID: 37909019. PMCID: PMC10613967.
  • Marchal MA, Moose DI, Varzavand A, Jordan NE, Taylor D, Tanas MR, Brown JA, Henry MD, Stipp CS. (2023) Abl kinases can function as suppressors of tumor progression and metastasis. Front Oncol. Sep 8; 13:1241056. DOI: 10.3389/fonc.2023.1241056. PMID: 37746268. PMCID: PMC10514900.
  • Rieth, J. M., Swami, U., Mott, S. L., Zanaty, M., Henry, M. D., Bossler, A. D., Greenlee, J. D., Zakharia, Y., Vanneste, M., Jennings, B. & Milhem, M. M. (2021). Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy. Cancers (Basel) 13 (7) 1489. PMID: 33804910.
  • Henry, M. D. (1996). Analysis of tau and radixin: Two accessory proteins of the cytoskeleton in mammalian cells. United States – Massachusetts: Massachusetts Institute of Technology.
  • Chen, H., Osman, S. Y., Moose, D. L., Vanneste, M., Anderson, J. L., Henry, M. D. & Anand, R. K. (2023). Quantification of capture efficiency, purity, and single-cell isolation in the recovery of circulating melanoma cells from peripheral blood by dielectrophoresis. Lab Chip. DOI: 10.1039/d2lc01113a. PMID: 37185977.
  • Bi, J., Witt, E., Voltarelli, V. A., Feig, V. R., Venkatachalam, V., Boyce, H., McGovern, M., Gutierrez, W. R., Rytlewski, J. D., Bowman, K. R., Rhodes, A. C., Cook, A. N., Muller, B. N., Smith, M. G., Ramos, A. R., Panchal, H., Dodd, R. D., Henry, M. D., Mailloux, A., Traverso, G., Otterbein, L. E. & Byrne, J. D. (2023). Low-Cost, High-Pressure-Synthesized Oxygen-Entrapping Materials to Improve Treatment of Solid Tumors. Adv Sci (Weinh) e2205995. DOI: 10.1002/advs.202205995. PMID: 36727291.